- Home
- SLRX vs VTAK Comparison
SLRX vs VTAK Comparison
Compare SLRX & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- VTAK
- Stock Information
- Founded
- SLRX N/A
- VTAK 2002
- Country
- SLRX United States
- VTAK United States
- Employees
- SLRX N/A
- VTAK N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- SLRX Health Care
- VTAK Health Care
- Exchange
- SLRX Nasdaq
- VTAK Nasdaq
- Market Cap
- SLRX 2.9M
- VTAK 3.1M
- IPO Year
- SLRX N/A
- VTAK 2018
- Fundamental
- Price
- SLRX $4.65
- VTAK $2.44
- Analyst Decision
- SLRX
- VTAK
- Analyst Count
- SLRX 0
- VTAK 0
- Target Price
- SLRX N/A
- VTAK N/A
- AVG Volume (30 Days)
- SLRX 124.5K
- VTAK 3.1M
- Earning Date
- SLRX 08-12-2025
- VTAK 08-11-2025
- Dividend Yield
- SLRX N/A
- VTAK N/A
- EPS Growth
- SLRX N/A
- VTAK N/A
- EPS
- SLRX N/A
- VTAK N/A
- Revenue
- SLRX N/A
- VTAK $600,000.00
- Revenue This Year
- SLRX N/A
- VTAK $822.86
- Revenue Next Year
- SLRX N/A
- VTAK $168.42
- P/E Ratio
- SLRX N/A
- VTAK N/A
- Revenue Growth
- SLRX N/A
- VTAK 37.62
- 52 Week Low
- SLRX $4.61
- VTAK $2.39
- 52 Week High
- SLRX $108.00
- VTAK $33.06
- Technical
- Relative Strength Index (RSI)
- SLRX 31.39
- VTAK 38.86
- Support Level
- SLRX $4.61
- VTAK $2.39
- Resistance Level
- SLRX $6.28
- VTAK $2.59
- Average True Range (ATR)
- SLRX 0.54
- VTAK 0.18
- MACD
- SLRX 0.05
- VTAK 0.00
- Stochastic Oscillator
- SLRX 1.92
- VTAK 6.44
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.